Ono-4059 (Gs-4059), a Next Generation BTK Inhibitor, Monotherapy in Patients With B-Cell Malignancies in the Japanese Phase 1, Dose-Escalation Study

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_185
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement

SLAS Discovery
BiochemistryBiotechnologyAnalytical ChemistryMolecular Medicine
2018English

Bruton Tyrosine Kinase Inhibitor ONO/GS-4059: From Bench to Bedside

Oncotarget
Oncology
2016English

Tanespimycin Monotherapy in Relapsed Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study

British Journal of Haematology
Hematology
2010English

A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies

Cancer
Cancer ResearchOncology
2018English

Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2017English

A First-In-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2017English

Phase 1 Dose-Escalation Study With LEC/Chtnt-3 and Toceranib Phosphate (Palladia) in Dogs With Spontaneous Malignancies

Journal of Cancer Science & Therapy
2015English

Preliminary Results of a Phase 1 Dose Escalation Study of the First-In-Class Anti-Cd74 Antibody Drug Conjugate (Adc), Stro-001, in Advanced B-Cell Malignancies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination With Bevacizumab in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy